Indivior Pharmaceuticals, Inc.
INDV
$33.34
$0.742.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.01% | 3.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.01% | 3.97% | |||
| Cost of Revenue | 21.74% | -11.54% | |||
| Gross Profit | 12.69% | 7.20% | |||
| SG&A Expenses | 16.54% | -15.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -200.00% | -- | |||
| Total Operating Expenses | 13.64% | -14.29% | |||
| Operating Income | 14.66% | 63.38% | |||
| Income Before Tax | 118.92% | -40.32% | |||
| Income Tax Expenses | -320.00% | -111.36% | |||
| Earnings from Continuing Operations | 142.86% | 133.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 142.86% | 133.33% | |||
| EBIT | 14.66% | 63.38% | |||
| EBITDA | 13.45% | 67.61% | |||
| EPS Basic | 144.05% | 133.33% | |||
| Normalized Basic EPS | 22.62% | 75.81% | |||
| EPS Diluted | 139.33% | 135.71% | |||
| Normalized Diluted EPS | 21.91% | 71.74% | |||
| Average Basic Shares Outstanding | -0.49% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.09% | 2.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||